<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Infection Immunity and Inflammation</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/77BF0D18-BFAB-4455-B9AF-E84630C54A26"><gtr:id>77BF0D18-BFAB-4455-B9AF-E84630C54A26</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Leyland</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D6401838-BE8F-43B6-B46C-997DD23C1404"><gtr:id>D6401838-BE8F-43B6-B46C-997DD23C1404</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Bradding</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801164"><gtr:id>8B866B13-7B80-47C1-BAF0-006D36EBA6C8</gtr:id><gtr:title>The role of cell adhesion molecule-1 in human mast cell biology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801164</gtr:grantReference><gtr:abstractText>Mast cells are white blood cells which are important in maintaining normal organ function and protection from bacterial infections, but also important for contributing to the development of many diseases such as asthma, allergy, lung fibrosis (scarring) and atherosclerosis (hardening of the arteries). They exert their effects through the release of many diverse chemicals: when release of these is limited the effects are beneficial, when excessive then they become harmful. For mast cells to function normally, they interact with many cell types present in the tissues by sticking to them, a process known as adhesion. By adhering or sticking to other cells, this allows mast cells to direct their chemicals to specific cell types accurately. We have found that mast cells express an interesting protein on their surface called cell adhesion molecule 1 (CADM1). Mast cells are unusual in that this protein is not expressed by other white blood cells. CADM1 facilitates the interaction of mast cells with airway muscle cells and cells called fibroblasts, allowing the cells to stick together and thus communicate. Very little is known about how CADM1 functions, or what it is it binds to on airway muscle and fibroblasts. In this project we therefore wish to work out how CADM1 regulates mast cell function, and how it interacts with other cell types that mast cells stick to. We will use methods that are well established in our laboratory to tackle this. These include a specialist technique called RNA interference which inhibits the gene which produces CADM1 in mast cells. The results of this research project will highlight ways in which the effects of CADM1 can be controlled and may provide entirely new ways of controlling mast cell function in both health and disease.</gtr:abstractText><gtr:technicalSummary>Mast cells play a key role in the pathophysiology of asthma and many other diverse diseases including pulmonary fibrosis. Current treatments for these diseases are either ineffective or carry unacceptable side effects for a number of patients; in consequence, new approaches to therapy are needed urgently. Mast cells express cell adhesion molecule 1 (CADM1) which plays an important role in their interaction with structural cells including airway smooth muscle (ASM) and fibroblasts, facilitating both cell-cell adhesion and mast cell proliferation. The ligand for CADM1 on ASM and the mechanisms through which CADM1 achieves its biological effects in human mast cells are unknown. Our central hypotheses are that CADM1 plays a central role in mast cell interactions with airway smooth muscle cells and fibroblasts, and operates in a critical and co-operative manner with the stem cell factor receptor (c-kit, CD117). The aim of this proposal is to identify:

1. The effects of CADM1 overexpression, knockdown and mutation on human mast cell adhesion, proliferation, survival, migration and secretion. This will be investigated in the human mast cell line HMC-1 and primary human lung mast cells (HLMC) using adenoviral delivery of CADM1 dominant-negative mutants and short hairpin (sh)RNA. 
2. The effects of CADM1 overexpression, knockdown and mutation on CD117 expression, function and tyrosine phosphorylation in HLMC and HMC-1.
3. The ligand(s) for CADM1 expressed by primary human ASM (likely candidates are Nectin-3 and Necl-1: to be assessed by RT-PCR, Western blotting, flow cytometry, adhesion assays).
4. The effects of CADM1 mediated signals on primary human ASM proliferation and differentiation (shRNA knockdown, dominant-negative mutants, blocking antibodies).
5. The role of CADM1 in human mast cell adhesion to primary human airway fibroblasts and the functional consequences (adhesion and proliferation assays in the presence of CADM1 blocking antibodies and following CADM1 knockdown/mutation).

The results of this research project will delineate the role of CADM1 in human mast cell biology, and may offer a novel approach to the modulation of mast cell function in health and disease.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-10</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-03-11</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>282261</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Unit, University Hospitals of Leicester NHS Trust</gtr:department><gtr:description>NIHR Biomedical Research Unit</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>BB67BC44-335B-48E0-8F22-738FFAF63721</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Aquired new knowledge with respect to the role of CADM1 isoforms in human mast cell biology - CADM1 mediates human lung mast cell (HLMC) homotypic adhesion, promotes HLMC survival, regulates expression of KIT, and mediates adhesion of HLMC to fibroblasts and airway smooth muscle</gtr:description><gtr:id>DFEFDEC7-119C-4A2D-A8EF-B5B5EC01E589</gtr:id><gtr:impact>As above. Manuscript submitted for publication</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Regulation of HLMC function by CADM1</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Adenovirus containing shRNA and DNA to CADM1, allowing highly efficient knockdown and overexpression respectively in primary human lung mast cells</gtr:description><gtr:id>46DBF5BD-F6F2-4198-8ED6-8B3F5BAFC35F</gtr:id><gtr:impact>Aquired new knowledge with respect to the role of CADM1 isoforms in human mast cell biology - CADM1 mediates human lung mast cell (HLMC) homotypic adhesion, promotes HLMC survival, regulates expression of KIT, and mediates adhesion of HLMC to fibroblasts and airway smooth muscle. CADM1 regulates mast cell integrin function.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>adenoviral packaged CADM shRNA and DNA</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In silico analysis of CADM1 interactions with one of its ligands, nectin-3. Predictive model of interacting sites of both proteins.</gtr:description><gtr:id>1CC16232-038E-4E9A-BE2E-5F96064AF4DF</gtr:id><gtr:impact>None yet</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>In silico model of CADM1 interaction with Nectin-3</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>cDNA clones for CADM1 isoforms and mutants - expressed in plasmids which will allow delivery by adenovirus for studies of cell localisation, cell function, protein interactions, cell signalling.</gtr:description><gtr:id>CB23B8B8-F726-4D8F-9734-F43A5E695F0D</gtr:id><gtr:impact>No notable impacts yet</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>cDNA clones</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7E9F492-D7A0-4130-A1E7-571ADAA03B8A"><gtr:id>D7E9F492-D7A0-4130-A1E7-571ADAA03B8A</gtr:id><gtr:title>CADM1 is expressed as multiple alternatively spliced functional and dysfunctional isoforms in human mast cells.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/756765a887832079eec2a173f77d1c61"><gtr:id>756765a887832079eec2a173f77d1c61</gtr:id><gtr:otherNames>Moiseeva EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11E1AF63-C998-4900-BDE5-D696C8534204"><gtr:id>11E1AF63-C998-4900-BDE5-D696C8534204</gtr:id><gtr:title>CADM1 is a key receptor mediating human mast cell adhesion to human lung fibroblasts and airway smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/756765a887832079eec2a173f77d1c61"><gtr:id>756765a887832079eec2a173f77d1c61</gtr:id><gtr:otherNames>Moiseeva EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58285068-845D-4E96-B2E7-9B84B620DCC6"><gtr:id>58285068-845D-4E96-B2E7-9B84B620DCC6</gtr:id><gtr:title>CADM1 isoforms differentially regulate human mast cell survival and homotypic adhesion.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/756765a887832079eec2a173f77d1c61"><gtr:id>756765a887832079eec2a173f77d1c61</gtr:id><gtr:otherNames>Moiseeva EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/33BFB66B-B35E-426A-80A8-06A9D9EA4967"><gtr:id>33BFB66B-B35E-426A-80A8-06A9D9EA4967</gtr:id><gtr:title>CADM1 controls actin cytoskeleton assembly and regulates extracellular matrix adhesion in human mast cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/756765a887832079eec2a173f77d1c61"><gtr:id>756765a887832079eec2a173f77d1c61</gtr:id><gtr:otherNames>Moiseeva EP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801164</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>